Intravenous Immunoglobulin therapy for anti-E hemolytic disease in the newborn

J Matern Fetal Neonatal Med. 2010 Sep;23(9):1059-61. doi: 10.3109/14767050903544751.

Abstract

Anti-E alloimmunisation is a less common cause of haemolytic disease in the newborn (HDN) and is usually associated with mild to moderate clinical manifestations, that are often less severe than anti-D immunisation. Conventional treatments for HDN are phototherapy and exchange transfusion, the latter still representing a high-risk procedure. Currently, intravenous immunoglobulin has been used as alternative treatment for HDN to reduce the need for exchange transfusion, as well as the length of phototherapy and hospitalisation. We report a case of anti-E HDN treated successfully with intravenous immunoglobulin, as adjuvant treatment to phototherapy.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Combined Modality Therapy
  • Erythroblastosis, Fetal / therapy*
  • Female
  • Humans
  • Immunization, Passive
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant, Newborn
  • Phototherapy
  • Pregnancy
  • Rh-Hr Blood-Group System / immunology

Substances

  • Adjuvants, Immunologic
  • Immunoglobulins, Intravenous
  • Rh-Hr Blood-Group System